KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Gains from Investment Securities (2016 - 2025)

Charles River Laboratories International has reported Gains from Investment Securities over the past 17 years, most recently at $802000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $802000.0 for Q4 2025, up 116.34% from a year ago — trailing twelve months through Dec 2025 was -$2.5 million (up 44.95% YoY), and the annual figure for FY2025 was -$2.5 million, up 44.95%.
  • Gains from Investment Securities for Q4 2025 was $802000.0 at Charles River Laboratories International, up from -$3.0 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for CRL hit a ceiling of $15.5 million in Q4 2022 and a floor of -$36.3 million in Q3 2022.
  • Median Gains from Investment Securities over the past 5 years was $110000.0 (2022), compared with a mean of -$1.4 million.
  • Peak annual rise in Gains from Investment Securities hit 2227.71% in 2022, while the deepest fall reached 3816.81% in 2022.
  • Charles River Laboratories International's Gains from Investment Securities stood at $664000.0 in 2021, then skyrocketed by 2227.71% to $15.5 million in 2022, then tumbled by 120.21% to -$3.1 million in 2023, then crashed by 57.12% to -$4.9 million in 2024, then surged by 116.34% to $802000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $802000.0 (Q4 2025), -$3.0 million (Q3 2025), and -$243000.0 (Q2 2025) per Business Quant data.